The Oncologist, Vol. 12, No. 8, 967-974, August 2007; doi:10.1634/theoncologist.12-8-967 © 2007 AlphaMed Press
Evolving Strategies for Combined-Modality Therapy for Locally Advanced Head and Neck CancerHead and Neck Oncology Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA Key Words. Head and neck cancer • Induction therapy • Sequential therapy • Combined modality • Treatment • SCCHN Correspondence: Marshall Posner, M.D., Head and Neck Oncology Program, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, SW430, Boston, Massachusetts 02115, USA. Telephone: 617-632-3090; Fax: 617-632-4448; e-mail: marshall_posner{at}dfci.harvard.edu Received January 13, 2006; accepted for publication May 15, 2007.
Despite continual advances in the treatment of head and neck cancer, disease-free survival, functional outcome, toxicity of therapy, and overall survival remain less than optimal. While traditional treatment has focused on surgical resection with or without radiation and chemoradiotherapy, newer combined-modality regimens may offer patients a better prognosis, organ preservation, and less morbidity. In this paper, single agents and doublet therapy are reviewed, as are emerging data on the utility of induction therapy, chemoradiotherapy, and surgery as a sequential treatment regimen.
Disclosure of potential conflicts of interest is found at the end of this article.
This article has been cited by other articles:
Copyright © 2007 by AlphaMed Press. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||